⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplemental Figure 3 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Claire Gallois Matteo Landi Julien Taı̈eb Marine Sroussi Bahar Saberzadeh-Ardestani Antoine Cazelles Sara Lonardi Francesca Bergamo Rossana Intini Giulia Maddalena Filippo Pietrantonio Francesca Corti Margherita Ambrosini Antonia Martinetti Marco Maria Germani Chiara Boccaccio Guglielmo Vetere Sophie Mouillet‐Richard Aurélien de Reyniès Frank A. Sinicrope Chiara Cremolini Pierre Laurent‐Puig

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Tumor mutational burden and diagnosed Lynch syndrome in patients with MSI-high status determined by only one method

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gallois et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522828 https://doi.org/10.1158/1078-0432.27033136.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 3 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
2Supplemental Figure 1 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
3Supplemental Figure 1 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
4Supplemental Figure 2 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
5Supplemental Figure 2 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024

Supplemental Figure 5 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
Supplemental Figure 5 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
Supplemental Figure 6 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024